SLC5A2 and heart failure: Prasada et al. demonstrated in a recent study that the prognostic impact is also associated with the type of heart failure (reduced ejection fraction vs. preserved ejection fraction), as well as the associated treatment, as it is known that SGLT2 inhibitors decrease the risk of heart failure independently of the presence or absence of diabetes mellitus.